Baylor College of Medicine

A Study of Arbaclofen in Subjects with 16p11.2 deletion (H-46760)



This study will examine the safety, tolerability and efficacy of arbaclofen for the treatment of neurodevelopmental impairments in children with 16p11.2 deletion

What does the study include?
4 to 5 visits with your child at Texas Children’s Hospital in Houston, TX. Travel expenses are covered.

What will you do at the visits? 

  • You will complete several questionnaires.
  • Your child will complete some medical exams, behavior tasks, and speech-language tasks.

To participate in this study you must:

  • Have the 16p11.2 (BP4-BP5) deletion
  • Be between the ages of 5-17 years of age at screening
  • Have neurodevelopmental challenges that require therapy or educational supports

IRB: H-46760




Back to topback-to-top